The selective expression of CCR5 and CXCL13 in neoantigen-specific T cells further suggests that a key feature of CPI-responsiveness is the ability to sustain ongoing priming and recruitment of tumour reactive T cells supported by CXCR5+ lymphocytes, which may include T and B cells (Helmink et al., 2020). The gene discussed is CXCR5; the disease is neoplasm.